Clinical Trial · NCT01190566

PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

Overview

The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI, dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To compare the performances of dynamic contrast-enhanced MRI using parametric response map analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients

Sponsor

Seoul National University Hospital

Contacts

Woo Kyung Moon, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01190566

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

RGD

Isotope(s):

Target(s):

αvβ3

Ligand Class: Small Molecules

Eligibility

Inclusion

Clinical stage IIb, IIIa, IIIb, IIIc
Must have measurable disease
Adequate, bone marrow, liver, heart, and renal function
Performance status of ECOG 0-2
* Pathologically confirmed breast cancer

Exclusion

Psychological disease or seizure
History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina
Active bacterial infection
Pregnant or lactating women
* Prior history of cancer besides breast cancer